Invitae Announces Partnership with Epic to Streamline Genetic Testing

Rhea-AI Summary

On March 21, 2023, Invitae (NYSE: NVTA) announced a partnership with Epic to enhance access to genetic testing results for healthcare providers and patients. This collaboration aims to integrate genetic test results into Epic's Aura diagnostic suite, simplifying workflows and supporting personalized medicine. The initiative is positioned to improve patient outcomes by identifying at-risk individuals and enabling early detection. Notably, both companies emphasize the potential of this partnership to optimize healthcare delivery across leading organizations in the Epic community.

Positive

• Partnership with Epic to streamline genetic testing access.
• Integration into Epic's Aura suite enhances workflows for providers.
• Aims to improve patient outcomes through personalized medicine.

Negative

• The company has a history of losses.
• Risks associated with competition and maintaining customer relationships.
• Potential issues with scaling infrastructure to meet demand.

– Collaboration will simplify providers' and patients' access to discrete test results that can inform more precise, personalized medicine –

SAN FRANCISCO, March 21, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced its partnership with Epic, an industry-leading healthcare software company. 

Through Aura, Epic's specialty diagnostics suite, Invitae will streamline interactions with provider organizations in the Epic community, making test result information available in providers' usual workflows so that it's easier to use genetic insights to inform treatment decisions. 

"Genetic testing can inform some of the most important care decisions in patients' lives, and Invitae is making it more accessible to both patients and providers across the Epic community," said Dave Fuhrmann, senior vice president of research and development at Epic. "Aura will help them do so by further enabling precision medicine at many of the nation's leading healthcare organizations."

"Our use of Aura allows patients and providers to seamlessly access genetic testing that can help identify at-risk individuals, enhance early detection and better personalize treatments with the goals of achieving better outcomes and reducing the burden on the broader healthcare system," said Robert Nussbaum, M.D., chief medical officer at Invitae.

For more information, visit Invitae.com. 

About Invitae 
Invitae (NYSE: NVTA) is a leading medical genetics company trusted by millions of patients and their providers to deliver timely genetic information using digital technology. We aim to provide accurate and actionable answers to strengthen medical decision-making for individuals and their families. Invitae's genetics experts apply a rigorous approach to data and research, serving as the foundation of their mission to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people.

To learn more, visit invitae.com and follow for updates on Twitter, Instagram, Facebook and LinkedIn @Invitae.

Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the company's beliefs regarding its collaboration with Epic, including that the partnership will simplify providers' and patients' access to discrete test results that can inform more precise, personalized medicine. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the impact of inflation and the current economic environment on the company's business; the company's ability to grow its business in a cost-efficient manner; the company's history of losses; the company's ability to maintain important customer relationships; the company's ability to compete; the company's need to scale its infrastructure in advance of demand for its tests and to increase demand for its tests; the applicability of clinical results to actual outcomes; risks associated with litigation; the company's ability to use rapidly changing genetic data to interpret test results accurately and consistently; security breaches, loss of data and other disruptions; laws and regulations applicable to the company's business; and the other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Annual Report on Form 10-K for the year ended December 31, 2022. These forward-looking statements speak only as of the date hereof, and Invitae Corporation disclaims any obligation to update these forward-looking statements.

Invitae PR contact: 
Renee Kelley 
pr@invitae.com  
(628) 213-3283

View original content to download multimedia:https://www.prnewswire.com/news-releases/invitae-announces-partnership-with-epic-to-streamline-genetic-testing-301776648.html

SOURCE Invitae Corporation

FAQ

What does the partnership between Invitae and Epic entail?

The partnership aims to streamline access to genetic testing results for providers and patients through Epic's Aura diagnostics suite.

How will the collaboration impact patient care?

The collaboration is designed to enhance early detection of at-risk individuals and facilitate personalized treatment options.

When was the partnership between Invitae and Epic announced?

The partnership was announced on March 21, 2023.

What is the stock symbol for Invitae?

Invitae's stock symbol is NVTA.

What are the risks associated with Invitae's business?

Risks include a history of losses, competition, and challenges in scaling infrastructure.